Evidence-based treatment for low-risk basal cell carcinoma

Affiliations

¹ Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Salford Royal NHS Foundation Trust, and Manchester Royal Infirmary, Manchester M6 8HD, UK. Electronic address: john.lear@srft.nhs.uk.

Comment

John T Lear. Lancet Oncol. 2014 Jan.

. 2014 Jan;15(1):12-3.

doi: 10.1016/S1470-2045(13)70582-5. Epub 2013 Dec 11.

¹ Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Salford Royal NHS Foundation Trust, and Manchester Royal Infirmary, Manchester M6 8HD, UK. Electronic address: john.lear@srft.nhs.uk.

No abstract available

Comment on

Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, Williams HC; Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma (SINS) study group. Bath-Hextall F, et al. Lancet Oncol. 2014 Jan;15(1):96-105. doi: 10.1016/S1470-2045(13)70530-8. Epub 2013 Dec 11. Lancet Oncol. 2014. PMID: 24332516 Clinical Trial.